title: Helicobacter pylori eradication and histopathological esophagitis in dyspeptic patients.
abstract: BACKGROUND
  The association of Helicobacterpylori with peptic ulcer disease, atrophic gastritis, gastric adenocarcinoma, MALT (mucosa associated lymphoid tissue) lymphoma is well recognized.
  
  
  OBJECTIVE
  This study was conducted to see whether there was any relation between H. pylori eradication and reflux esophagitis in Iran.
  
  
  METHODS
  Eligible dyspeptic patients referred to Gastroenterology clinic in Baqiyatollah hospital were endoscopied and evaluated for endoscopic and pathologic esophagitis and the H. pylori infection status was determined by rapid urease test. H. pylori infection was treated by an anti H. pylori drug regimen and successfully eradicated patients according to negative C14 urea breath test were followed and re-endoscopy was performed 6-9 months after the end of treatment.
  
  
  RESULTS
  From 175 eligible patients, 54% were H. pylori positive, 68 of them (72%) had successful H.P. eradication and 64 patients completed the follow-up. The rate of histopathologic inflammatory esophagitis was higher in second endoscopy, compared with that of first endoscopy, i.e., before H. pylori eradication (75% vs 40.6%) (p < 0.05). Progression of pathological esophagitis was seen in 56.3% of patients between the two endoscopic evaluations in spite of no change in clinical and endoscopic findings. There were no significant differences in dietary and smoking habits and body weights on re-endoscopy session compared with that of the first endoscopy visit (p > 0.05).
  
  
  CONCLUSIONS
  This study suggests that H. pylori eradication in dyspeptic patients may lead to increased frequency of histopathological esophagitis. Hence, In patients presenting with symptoms of dyspepsia, a cautious approach should be exercised if H. pylori eradication is being contemplated.
authors.affiliation: GI and Liver Research Center, Baqiatallah University of Medical Sciences, Tehran, Iran.
authors.forename: Mohsen
authors.initials: M
authors.lastname: Amini
authors.forename: Ashraf
authors.initials: A
authors.lastname: Karbasi
authors.forename: Hossein
authors.initials: H
authors.lastname: Khedmat
authors.forename: Mojgan
authors.initials: M
authors.lastname: Jeihounian
mesh_terms: D000328:Adult; D000658:Amoxicillin / Q000008:administration & dosage; D000863:Antacids / Q000008:administration & dosage; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D000897:Anti-Ulcer Agents / Q000008:administration & dosage; D001729:Bismuth / Q000008:administration & dosage; D018450:Disease Progression; D004359:Drug Therapy, Combination; D004415:Dyspepsia / Q000188:drug therapy; D004942:Esophagitis, Peptic / Q000209:etiology* / Q000473:pathology*; D004945:Esophagoscopy; D004947:Esophagus / Q000473:pathology; D005260:Female; D005764:Gastroesophageal Reflux / Q000209:etiology* / Q000473:pathology*; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D007492:Iran; D008297:Male; D008795:Metronidazole / Q000008:administration & dosage; D008875:Middle Aged; D009092:Mucous Membrane / Q000473:pathology; D009853:Omeprazole / Q000008:administration & dosage
chemical_list: D000863:Antacids; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D008795:Metronidazole; D000658:Amoxicillin; D009853:Omeprazole; D001729:Bismuth